{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"Year 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Year 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"description":"The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5.\n\nDefinition of Disease Progression:\n\nMM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%.\n\nCLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells.\n\nAML/ALL: Any incidence of relapse (\\>5% blasts) by evaluation of the bone marrow aspirate.\n\nCML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by \\>25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis.\n\nMDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (\\>5%) or worsening cytopenia or cytogenetic evidence of recurrence.","groups":[{"description":"Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0\n\nTherapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.\n\nBusulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.\n\nIV Busulfan is available and diluted and administered per package insert guidelines.\n\nCyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including","id":"OG000","title":"Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Years 1, 2, 3, and 5","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of analyzed participants"}